Clinical neuropharmacology
August 1, 1994
R B Rosse, J P Collins, M Fay-Mccarthy et al.
62 citations
Cocaine-induced psychosis and PCP-induced psychosis each resemble some symptoms of schizophrenia but differ in their specific features. In a retrospective study of 34 male crack-cocaine-dependent patients without other psychiatric disorders and 16 actively psychotic men with schizophrenia, certain First Rank Schneiderian Symptoms such as thought broadcasting and thought withdrawal were more common in the schizophrenic group. In a separate group of 22 cocaine addicts with past use of both cocaine and PCP, the frequency of these symptoms during intoxication was similar for both drugs.
Clinical neuropharmacology
October 1, 1995
R B Rosse, J Mastropaolo, D M Sussman et al.
MK-801, a compound that blocks NMDA glutamate receptors, causes hyperactivity, repetitive behaviors, and explosive jumping (popping) in mice. A computerized system was developed to automatically measure popping and hyperactivity by detecting vertical platform movements. This method quantifies the number, force, and duration of jumps more precisely than human observation. The antipsychotic haloperidol significantly reduced both popping and hyperactivity caused by MK-801. The authors suggest this automated approach could improve preclinical screening of potential antipsychotic drugs and help clarify the mechanisms behind MK-801-induced behaviors.
Clinical neuropharmacology
June 1, 1993
A Hitri, D A O'Connor, J M Cohen et al.
MK-801, a high-affinity analogue of phencyclidine (PCP), was given to mice to stimulate behaviors resembling those seen in schizophrenia. Apomorphine, a dopamine agonist, was also given to a separate group of mice for comparison. Visual observation showed that apomorphine caused intense gnawing and sniffing, while MK-801 did not produce gnawing. Automated measurements revealed frequent differences between the behaviors induced by the two drugs. The authors suggest that a compound which reduces PCP-stimulated behaviors but not apomorphine-stimulated ones might be an effective antipsychotic with fewer side effects than current dopamine-blocking drugs.